CRYO CELL INTERNATIONAL INC
For the period ended Feb 29, 2024. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Feb 29, 2024 · Filed Apr 15, 2024
CCEL$4.89-1.2%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets
| (Unaudited) | ||
|---|---|---|
| February 29, | November 30, | |
| 2024 | 2023 | |
| ASSETS | ||
| Current Assets | ||
| Cash and cash equivalents | $247,112 | $406,067 |
| Marketable securities | 732,481 | 574,183 |
| Accounts receivable (net of allowance for | ||
| doubtful accounts of $3,939,638 and $3,822,300, respectively) | 6,726,893 | 6,576,240 |
| Prepaid expenses | 535,295 | 615,407 |
| Inventory, current portion | 755,160 | 768,877 |
| Swap contract | 76,825 | 122,113 |
| Other current assets | 378,310 | 389,950 |
| Total current assets | 9,452,076 | 9,452,837 |
| Property and Equipment-net | 21,605,273 | 20,996,883 |
| Other Assets | ||
| Investment - Tianhe stock | 308,000 | 308,000 |
| Intangible assets, net | 972,154 | 989,121 |
| Inventory, net of current portion | 5,223,980 | 5,260,119 |
| Goodwill | 1,941,411 | 1,941,411 |
| Deferred tax assets | 20,492,749 | 20,492,749 |
| Operating lease right-of-use asset | 958,022 | 1,033,157 |
| Deposits and other assets, net | 757,109 | 746,493 |
| Total other assets | 30,653,425 | 30,771,050 |
| Total assets | $61,710,774 | $61,220,770 |
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $2,996,658 | $3,174,584 |
| Accrued expenses | 3,916,898 | 5,170,809 |
| Note payable | 168,623 | 165,641 |
| Line of credit | 1,972,728 | 1,222,728 |
| Current portion of operating lease liability | 253,981 | 225,686 |
| Duke license agreement liability | 666,667 | 1,200,000 |
| Deferred revenue | 9,394,821 | 9,704,553 |
| Total current liabilities | 19,370,376 | 20,864,001 |
| Other Liabilities | ||
| Deferred revenue, net of current portion | 42,603,661 | 41,186,800 |
| Contingent consideration | 39,050 | 44,226 |
| Note payable, net of current portion and debt issuance costs | 8,391,738 | 8,430,037 |
| Operating lease long-term liability | 768,961 | 851,938 |
| Long-term liability - revenue sharing agreements | 875,000 | 875,000 |
| Total other liabilities | 52,678,410 | 51,388,001 |
| Total liabilities | 72,048,786 | 72,252,002 |
| Commitments and contingencies (Note 9) | — | — |
| Stockholders' Deficit | ||
| Preferred stock ($.01 par value, 500,000 authorized and none issued and outstanding) | — | — |
| Series A Junior participating preferred stock ($.01 par value, 20,000 authorized and none issued and outstanding) | — | — |
| Common stock ($.01 par value, 20,000,000 authorized; 14,849,246 issued and 8,254,977 outstanding as of February 29, 2024 and 14,849,246 issued and 8,286,785 outstanding as of November 30, 2023) | 148,492 | 148,492 |
| Additional paid-in capital | 43,718,498 | 43,411,143 |
| Treasury stock, at cost | (23,602,061) | (23,431,685) |
| Accumulated deficit | (30,602,941) | (31,159,182) |
| Total stockholders' deficit | (10,338,012) | (11,031,232) |
| Total liabilities and stockholders' deficit | $61,710,774 | $61,220,770 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.